US judge bars copies of Lilly weight-loss drug

[StopCraving_12]

"Small compounding pharmacies must halt selling copies immediately, larger facilities by March 19"

https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-denies-injunction-stop-bar-copies-lilly-weight-loss-drug-2025-03-06/

 

[Morbius]

Man, things gonna get interesting.

(Why do you get an extension if you are a bigger company? If anything it ought to be the reverse, a bigger business is more likely to weather a loss in revenue.)

 

[Bunny]

I'm in the UK where regulations are being tightened so I'm watching this with interest

 

[keangkong]

Man, things gonna get interesting.

(Why do you get an extension if you are a bigger company? If anything it ought to be the reverse, a bigger business is more likely to weather a loss in revenue.)

Because the 503B pharmacies are envisioned as compounding beforehand to meet a need. The 503As are only supposed to compound for specific patients. Strictly speaking, it's not size that counts, but the provision that of law that authorizes the compounding that makes a difference.

 

[keangkong]

"Small compounding pharmacies must halt selling copies immediately, larger facilities by March 19"

https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-denies-injunction-stop-bar-copies-lilly-weight-loss-drug-2025-03-06/

I know many compounding pharmacies plan to continue compounding. The FDA's announcement and the court ruling as to it affect only affect one exception to the ban on compounding of patented medications. There are many others. See Food Drug & Cosmetic Act §§ 503A (21 U.S.C. § 353a), 503B (21 U.S.C. § 353b). Despite me being a lawyer, this is far outside my area of expertise. But I have heard from lawyers from compounding pharmacies who say the plan on continuing to compound. I make no predictions about how this will all turn out. I'm not super interested in this topic right now simply because I believe the folks using compounding pharmacies ought to switch to grey.